0001601485-20-000004.txt : 20200623 0001601485-20-000004.hdr.sgml : 20200623 20200623161913 ACCESSION NUMBER: 0001601485-20-000004 CONFORMED SUBMISSION TYPE: D PUBLIC DOCUMENT COUNT: 1 ITEM INFORMATION: 06b FILED AS OF DATE: 20200623 DATE AS OF CHANGE: 20200623 EFFECTIVENESS DATE: 20200623 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Angion Biomedica Corp. CENTRAL INDEX KEY: 0001601485 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 113430072 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: D SEC ACT: 1933 Act SEC FILE NUMBER: 021-369538 FILM NUMBER: 20982096 BUSINESS ADDRESS: STREET 1: 456 MONTGOMERY STREET STREET 2: SUITE 1200 CITY: SAN FRANCISCO STATE: CA ZIP: 94104 BUSINESS PHONE: (415) 655-4899 MAIL ADDRESS: STREET 1: 456 MONTGOMERY STREET STREET 2: SUITE 1200 CITY: SAN FRANCISCO STATE: CA ZIP: 94104 D 1 primary_doc.xml X0708 D LIVE 0001601485 Angion Biomedica Corp. 456 Montgomery Street Suite 1200 San Francisco CA CALIFORNIA 94104 (415) 655-4899 DELAWARE None None Corporation true Itzhak D. Goldberg 51 Charles Lindbergh Boulevard Uniondale NY NEW YORK 11553 Executive Officer Director Chairman Jay R. Venkatesan 456 Montgomery Street Suite 1200 San Francisco CA CALIFORNIA 94104 Executive Officer Director Chief Executive Officer Allen Nissenson 456 Montgomery Street Suite 1200 San Francisco CA CALIFORNIA 94104 Director Victor Ganzi 456 Montgomery Street Suite 1200 San Francisco CA CALIFORNIA 94104 Director Gil Omenn 456 Montgomery Street Suite 1200 San Francisco CA CALIFORNIA 94104 Director Karen Wilson 456 Montgomery Street Suite 1200 San Francisco CA CALIFORNIA 94104 Director Biotechnology Decline to Disclose 06b false 2020-06-12 false true true false 25000 GP Nurmenkari Inc. 153480 None None 22 Elizabeth Street SONO Square, Suite 1J Norwalk CT CONNECTICUT 06854 All States false T.R. Winston & Company, LLC 10571 None None 2049 Century Park East Suite 320 Los Angeles CA CALIFORNIA 90067 All States false 40000000 6695000 33305000 false 54 4000000 true 0 Assumes offering is fully subscribed. Each placement agent ("PA") will also receive warrants equal to 10% of the total amount of shares sold by such PA. 0 false Angion Biomedica Corp. /s/ Jay R. Venkatesan Jay R. Venkatesan Chief Executive Officer 2020-06-23